{"created":"2023-05-15T16:40:51.985183+00:00","id":15296,"links":{},"metadata":{"_buckets":{"deposit":"e155faf3-71f3-42e6-8496-5edb178ada08"},"_deposit":{"created_by":2,"id":"15296","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"15296"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00015296","sets":["29:30"]},"author_link":["56517","56514","56516","56522","56515","56521","56523","56524","56526","56525","56513","56520","56519","56518"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"338","bibliographicPageStart":"331","bibliographicVolumeNumber":"67","bibliographic_titles":[{"bibliographic_title":"Cancer chemotherapy and pharmacology"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment. METHODS: We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status </=3, age </=80 years, and stage IIIB-IV disease. In addition, EGFR mutations were analyzed in 24 patients. RESULTS: Multivariate analysis showed that favorable progression-free survival (PFS) after gefitinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were significantly correlated with response to gefitinib and serum SP-D levels before treatment was significantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS. CONCLUSIONS: The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to gefitinib.","subitem_description_type":"Abstract"}]},"item_2_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"The original publication is available at www.springerlink.com","subitem_description_type":"Other"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Cancer Chemotherapy and Pharmacology, 67(2), pp.331-338; 2011","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Berlin"}]},"item_2_relation_11":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"20401612","subitem_relation_type_select":"PMID"}}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s00280-010-1325-x","subitem_relation_type_select":"DOI"}}]},"item_2_relation_42":{"attribute_name":"関係URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"http://hdl.handle.net/10069/26688"}]}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© Springer-Verlag 2010"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00598397","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03445704","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"14320843","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yamaguchi, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Soda, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakamura, Yoichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takasu, Mineyo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tomonaga, Nanae"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakano, Hirofumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Doi, Seiji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakatomi, Katsumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nagashima, Seiji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takatani, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukuda, Minoru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hayashi, Tomayoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsukamoto, Kazuhiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kohno, Shigeru"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-23"}],"displaytype":"detail","filename":"CCP67_331.pdf","filesize":[{"value":"127.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"CCP67_331.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/15296/files/CCP67_331.pdf"},"version_id":"4c7e72d3-7592-4971-b1b1-f6c392d56c72"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Gefitinib","subitem_subject_scheme":"Other"},{"subitem_subject":"Non-small cell lung cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"SP-A","subitem_subject_scheme":"Other"},{"subitem_subject":"SP-D","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer."}]},"item_type_id":"2","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-05-26"},"publish_date":"2010-05-26","publish_status":"0","recid":"15296","relation_version_is_last":true,"title":["Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer."],"weko_creator_id":"2","weko_shared_id":2},"updated":"2023-05-15T19:06:01.462859+00:00"}